KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)R&D In ProcessReceivables - NetShares Repurchased
Ratios

Jazz Pharmaceuticals (JAZZ) Other Gross PP&E Adjustments (2016 - 2025)

Jazz Pharmaceuticals (JAZZ) has 16 years of Other Gross PP&E Adjustments data on record, last reported at $327.7 million in Q4 2025.

  • For Q4 2025, Other Gross PP&E Adjustments rose 39.87% year-over-year to $327.7 million; the TTM value through Dec 2025 reached $327.7 million, up 39.87%, while the annual FY2025 figure was $327.7 million, 39.87% up from the prior year.
  • Other Gross PP&E Adjustments reached $327.7 million in Q4 2025 per JAZZ's latest filing, up from $271.6 million in the prior quarter.
  • Across five years, Other Gross PP&E Adjustments topped out at $327.7 million in Q4 2025 and bottomed at -$188.5 million in Q1 2022.
  • Average Other Gross PP&E Adjustments over 5 years is $164.7 million, with a median of $221.0 million recorded in 2022.
  • Peak YoY movement for Other Gross PP&E Adjustments: skyrocketed 3789.8% in 2021, then crashed 449.69% in 2022.
  • A 5-year view of Other Gross PP&E Adjustments shows it stood at $299.2 million in 2021, then fell by 3.66% to $288.2 million in 2022, then plummeted by 34.34% to $189.3 million in 2023, then grew by 23.8% to $234.3 million in 2024, then soared by 39.87% to $327.7 million in 2025.
  • Per Business Quant database, its latest 3 readings for Other Gross PP&E Adjustments were $327.7 million in Q4 2025, $271.6 million in Q3 2025, and -$52.1 million in Q2 2025.